BeiGene's Tevimbra Gets Positive Opinion from Committee for Medicinal Products for Human Use

Dow Jones

May 27

By Denny Jacob

BeiGene's Tevimbra gets a highly sought after recommendation.

The oncology company said the European Medicines Agency's Committee for Medicinal Products for Human Use $(CHMP)$ issued a positive opinion of its treatment in combination with gemcitabine and cisplatin for adults with recurrent, not amenable to curative surgery or radiotherapy, or metastatic nasopharyngeal cancer.

Nasopharyngeal cancer is a type of head and neck cancer that starts in the upper throat passage that connects the nose to the lungs.

Mark Lanasa, chief medical officer, solid tumors at BeiGene, said the announcement marks a second positive CHMP opinion for Tevimbra this year.

Tevimbra is currently approved in the European Union as a first-line treatment for eligible patients with gastric or gastroesophageal junction adenocarcinoma, among other use cases.

Write to Denny Jacob at denny.jacob@wsj.com

(END) Dow Jones Newswires

May 27, 2025 07:12 ET (11:12 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2538468004"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2538468004\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2538468004?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-27 19:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2538468004","market":"sh","top_or_hot":-1,"title":"BeiGene's Tevimbra Gets Positive Opinion from Committee for Medicinal Products for Human Use","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Denny Jacob \n</p>\n<pre>\n \n</pre>\n<p>\n  BeiGene's Tevimbra gets a highly sought after recommendation. \n</p>\n<p>\n  The oncology company said the European Medicines Agency's Committee for Medicinal Products for Human Use <a href=\"https://laohu8.com/S/CHMP\">$(CHMP)$</a> issued a positive opinion of its treatment in combination with gemcitabine and cisplatin for adults with recurrent, not amenable to curative surgery or radiotherapy, or metastatic nasopharyngeal cancer. \n</p>\n<p>\n  Nasopharyngeal cancer is a type of head and neck cancer that starts in the upper throat passage that connects the nose to the lungs. \n</p>\n<p>\n  Mark Lanasa, chief medical officer, solid tumors at BeiGene, said the announcement marks a second positive CHMP opinion for Tevimbra this year. \n</p>\n<p>\n  Tevimbra is currently approved in the European Union as a first-line treatment for eligible patients with gastric or gastroesophageal junction adenocarcinoma, among other use cases. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 27, 2025 07:12 ET (11:12 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BeiGene's Tevimbra Gets Positive Opinion from Committee for Medicinal Products for Human Use</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeiGene's Tevimbra Gets Positive Opinion from Committee for Medicinal Products for Human Use\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-05-27 19:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Denny Jacob \n</p>\n<pre>\n \n</pre>\n<p>\n  BeiGene's Tevimbra gets a highly sought after recommendation. \n</p>\n<p>\n  The oncology company said the European Medicines Agency's Committee for Medicinal Products for Human Use <a href=\"https://laohu8.com/S/CHMP\">$(CHMP)$</a> issued a positive opinion of its treatment in combination with gemcitabine and cisplatin for adults with recurrent, not amenable to curative surgery or radiotherapy, or metastatic nasopharyngeal cancer. \n</p>\n<p>\n  Nasopharyngeal cancer is a type of head and neck cancer that starts in the upper throat passage that connects the nose to the lungs. \n</p>\n<p>\n  Mark Lanasa, chief medical officer, solid tumors at BeiGene, said the announcement marks a second positive CHMP opinion for Tevimbra this year. \n</p>\n<p>\n  Tevimbra is currently approved in the European Union as a first-line treatment for eligible patients with gastric or gastroesophageal junction adenocarcinoma, among other use cases. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 27, 2025 07:12 ET (11:12 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0307460666.USD","symbol_name":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2538468004","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2538468004","pubTimestamp":1748344320,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"BeiGene's Tevimbra gets a highly sought after recommendation.The oncology company said the European Medicines Agency's Committee for Medicinal Products for Human Use  issued a positive opinion of its treatment in combination with gemcitabine and cisplatin for adults with recurrent, not amenable to curative surgery or radiotherapy, or metastatic nasopharyngeal cancer.Nasopharyngeal cancer is a type of head and neck cancer that starts in the upper throat passage that connects the nose to the lungs.Mark Lanasa, chief medical officer, solid tumors at BeiGene, said the announcement marks a second positive CHMP opinion for Tevimbra this year.Tevimbra is currently approved in the European Union as a first-line treatment for eligible patients with gastric or gastroesophageal junction adenocarcinoma, among other use cases.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","ONC":"百济神州","BK1500":"做空集合股","BK1588":"回港中概股","BK4526":"热门中概股","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","CHMP":"冠军工业","BK1161":"生物科技","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK4139":"生物科技","06160":"百济神州","BK4087":"商业印刷","BK1583":"高瓴概念"},"translate_title":"百济神州的Tevimbra获得人用药品委员会的积极意见","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06160":1,"CHMP":1,"ONC":0.9},"content_text":"By Denny Jacob \n\n\n \n\n\n  BeiGene's Tevimbra gets a highly sought after recommendation. \n\n\n  The oncology company said the European Medicines Agency's Committee for Medicinal Products for Human Use $(CHMP)$ issued a positive opinion of its treatment in combination with gemcitabine and cisplatin for adults with recurrent, not amenable to curative surgery or radiotherapy, or metastatic nasopharyngeal cancer. \n\n\n  Nasopharyngeal cancer is a type of head and neck cancer that starts in the upper throat passage that connects the nose to the lungs. \n\n\n  Mark Lanasa, chief medical officer, solid tumors at BeiGene, said the announcement marks a second positive CHMP opinion for Tevimbra this year. \n\n\n  Tevimbra is currently approved in the European Union as a first-line treatment for eligible patients with gastric or gastroesophageal junction adenocarcinoma, among other use cases. \n\n\n \n\n\n  Write to Denny Jacob at denny.jacob@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 27, 2025 07:12 ET (11:12 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}